Home › Rectal Cancer › NCT03874559

Exosomes in Rectal Cancer

Exosomal as Correlative Biomarker in Clinical Outcomes in Patients Undergoing Neoadjuvant Chemoradiation Therapy for Rectal Cancer

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Male and Female Patients aged 18 and older
* histologically proven diagnosis of rectal adenocarcinoma
* will be receiving neoadjuvant chemoradiation therapy prior to a planned definitive surgical resection

Exclusion Criteria:

* Age less than 18.
* Patients who are unable or unwilling to undergo definitive surgery.
* Patients with a prior history of pelvic external beam radiation, brachytherapy, or chemotherapy.
* Patients with a prior history of cancer (excluding non-melanoma skin cancers).
* Patients who are immunocompromised.

About the study

The primary aims of this study is to characterize exosomal biomarker levels in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation therapy. Compare rates of exosomal expression before during and after chemoradiation therapy with pathologic response rates at the time of APR or LAR. The researchers will also examine the functionality of these exosomes in malignant colonic organoids and mouse models of colorectal cancer.

What is being tested

• Blood Draw (diagnostic test)

Sponsor: University of Kansas Medical Center · Participants: 30 · Started: Feb 13, 2018

Contact the study team

• Leah K Miller, MS · Phone: 913-588-3670
• Michelle Faucheux, RN · Phone: 913-588-9927

Official record on ClinicalTrials.gov — NCT03874559

Locations in the U.S.

Conditions

• Rectal Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.